This article is more than 5 years old. Information may no longer be current.

OctoPlus to develop controlled-release ophthalmic formulation

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

LEIDEN, Netherlands — OctoPlus has entered into a contract with ESBATech to develop a controlled-release formulation of a proprietary biological compound for ophthalmic indications, the company announced in a press release.

The contract includes process development, scale-up and manufacturing for pre-clinical studies of Locteron, which is part of a portfolio of projects focused on proprietary technologies, the release said.

The controlled-release formulation combines a proprietary eye care ingredient of ESBATech with PolyActive, a drug delivery technology from OctoPlus.

"Ophthalmology is a rapidly growing therapeutic area, and there is a strong and obvious need to reduce the injection frequency of drugs that are administered into the eye," Jan H. Egberts, MD, CEO of OctoPlus, said in the release.

Although the financial details were not disclosed, the project will make a material contribution to OctoPlus' revenue for 2011, the release said.